This review offers an in-depth examination of the mechanisms underlying the microbiome's defense against viral infections, with a specific focus on probiotic interventions. Mycotoxins, secondary compounds produced by microfungi, pose significant health risks. Yet, certain strains of Lactic Acid Bacteria (LAB) have exhibited remarkable efficacy in eliminating aflatoxin B1 (AFB1), the most toxic member of the aflatoxin family. Experimental setups demonstrated AFB1 binding to specific LAB strains, persisting even after gastric digestion. Laboratory studies revealed a potential protective mechanism wherein pre-incubation of probiotics with mycotoxins reduced their adhesion to mucus. Animal trials further underscored the benefits of oral probiotic administration, showcasing increased fecal excretion of mycotoxins and mitigation of associated health risks. Cyanobacteria-generated microcystins in drinking water pose a significant threat to human health. Probiotic bacteria, particularly strains like Bifidobacterium longum and Lactobacillus rhamnosus, have demonstrated exceptional efficacy in removing the cyanobacterial peptide toxin microcystin-LR. Optimized conditions resulted in rapid toxin elimination, highlighting the potential of probiotics in water purification. Engineered probiotics represent a cutting-edge approach to tailor microorganisms for specific therapeutic applications, exhibiting promise in treating metabolic disorders, Alzheimer's disease, and type 1 diabetes. Additionally, they serve as innovative diagnostic tools, capable of detecting pathogens and inflammation markers within the body. In the realm of antimicrobial peptide production, probiotics offer a promising platform, with genetically modified strains engineered to produce human β-defensin 2 (HBD2) for treating Crohn's disease, showcasing their potential in targeted theurapetic delivery. Biocontainment strategies have been implemented to prevent unintended environmental impacts.
Read full abstract